Abstract
We report the challenges of treating relapsing-remitting multiple sclerosis (MS) in a 31-year-old woman with long-standing chronic idiopathic neutropenia. The treatment with the disease-modifying therapy interferon-β was significantly complicated by a further fall in her generally low neutrophil count, to values below 0.5×10(9)/l, although this recovered rapidly when the treatment was stopped. We discuss the difficulties of balancing the risk of neutropenia with a risk of MS relapse.
MeSH terms
-
Adult
-
Disease Progression
-
Female
-
Humans
-
Immunologic Factors / adverse effects
-
Immunologic Factors / therapeutic use
-
Interferon-beta / administration & dosage
-
Interferon-beta / therapeutic use
-
Leukocyte Count
-
Multiple Sclerosis, Relapsing-Remitting / blood
-
Multiple Sclerosis, Relapsing-Remitting / complications*
-
Multiple Sclerosis, Relapsing-Remitting / drug therapy
-
Neutropenia / blood
-
Neutropenia / complications*
-
Neutropenia / drug therapy
-
Neutrophils / pathology
Substances
-
Immunologic Factors
-
Interferon-beta
Supplementary concepts
-
Neutropenia, severe chronic